{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T06:43:42Z","timestamp":1768632222675,"version":"3.49.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,8]],"date-time":"2022-02-08T00:00:00Z","timestamp":1644278400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.vaccine.2022.02.019","type":"journal-article","created":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T16:01:10Z","timestamp":1645459270000},"page":"1761-1767","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Immunogenicity and safety of an intradermal fractional third dose of ChAdOx1 nCoV-19\/AZD1222 vaccine compared with those of a standard intramuscular third dose in volunteers who previously received two doses of CoronaVac: A randomized controlled trial"],"prefix":"10.1016","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2862-948X","authenticated-orcid":false,"given":"Kriangkrai","family":"Tawinprai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7256-9982","authenticated-orcid":false,"given":"Taweegrit","family":"Siripongboonsitti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7522-8139","authenticated-orcid":false,"given":"Thachanun","family":"Porntharukchareon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kasiruck","family":"Wittayasak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nawarat","family":"Thonwirak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamonwan","family":"Soonklang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaidganok","family":"Sornsamdang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3048-2162","authenticated-orcid":false,"given":"Chirayu","family":"Auewarakul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nithi","family":"Mahanonda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2022.02.019_b0005","unstructured":"World Health Organization. WHO coronavirus (COVID-19) dashboard 2021, https:\/\/covid19.who.int\/table; 2021 [accessed 17 September 2021]."},{"key":"10.1016\/j.vaccine.2022.02.019_b0010","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2023184","article-title":"Repurposed antiviral drugs for COVID-19 \u2013 interim WHO Solidarity Trial results","volume":"384","author":"WHO Solidarity Trial Consortium","year":"2021","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.vaccine.2022.02.019_b0015","doi-asserted-by":"crossref","first-page":"e279","DOI":"10.1016\/S2666-5247(21)00069-0","article-title":"COVID-19 vaccine efficacy and effectiveness \u2013 the elephant (not) in the room","volume":"2","author":"Olliaro","year":"2021","journal-title":"Lancet Microbe"},{"issue":"4","key":"10.1016\/j.vaccine.2022.02.019_b0020","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.cell.2021.01.007","article-title":"Adaptive immunity to SARS-CoV-2 and COVID-19","volume":"184","author":"Sette","year":"2021","journal-title":"Cell"},{"issue":"10296","key":"10.1016\/j.vaccine.2022.02.019_b0025","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0140-6736(21)01429-X","article-title":"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey","volume":"398","author":"Tanriover","year":"2021","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.vaccine.2022.02.019_b0030","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.vaccine.2022.02.019_b0035","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S1473-3099(21)00568-5","article-title":"CoronaVac induces lower neutralising activity against variants of concern than natural infection","volume":"21","author":"Vacharathit","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2022.02.019_b0040","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1056\/NEJMc2108861","article-title":"Three doses of an mRNA COVID-19 vaccine in solid-organ transplant recipients","volume":"385","author":"Kamar","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2022.02.019_b0045","article-title":"How the world is (not) handling surplus doses and expiring vaccines","volume":"374","author":"Feinmann","year":"2021","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.vaccine.2022.02.019_b0050","doi-asserted-by":"crossref","first-page":"e2035693","DOI":"10.1001\/jamanetworkopen.2020.35693","article-title":"Immunogenicity and safety of reduced-dose intradermal vs intramuscular influenza vaccines: a systematic review and meta-analysis","volume":"4","author":"Egunsola","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"3","key":"10.1016\/j.vaccine.2022.02.019_b0055","doi-asserted-by":"crossref","first-page":"534","DOI":"10.3390\/vaccines8030534","article-title":"Vaccination into the dermal compartment: techniques, challenges, and prospects","volume":"8","author":"Hettinga","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2022.02.019_b0060","article-title":"Intradermal COVID-19 vaccination could solve supply problems","volume":"374","author":"Schweiger","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2022.02.019_b0065","first-page":"77","article-title":"Delivery systems for intradermal vaccination","volume":"351","author":"Kim","year":"2012","journal-title":"Curr Top Microbiol Immunol"},{"issue":"10282","key":"10.1016\/j.vaccine.2022.02.019_b0070","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/S0140-6736(21)00527-4","article-title":"WHO international standard for anti-SARS-CoV-2 immunoglobulin","volume":"397","author":"Kristiansen","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2022.02.019_b0075","doi-asserted-by":"crossref","first-page":"104820","DOI":"10.1016\/j.jcv.2021.104820","article-title":"Performance of the rapid high-throughput automated electrochemiluminescence immunoassay targeting total antibodies to the SARS-CoV-2 spike protein receptor binding domain in comparison to the neutralization assay","volume":"139","author":"Resman Rus","year":"2021","journal-title":"J Clin Virol"},{"issue":"9","key":"10.1016\/j.vaccine.2022.02.019_b0080","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/s41587-020-0631-z","article-title":"A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction","volume":"38","author":"Tan","year":"2020","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.vaccine.2022.02.019_b0085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0000845","article-title":"CD8+ T cells as a source of IFN-gamma production in human cutaneous leishmaniasis","volume":"4","author":"Nateghi Rostami","year":"2010","journal-title":"PLoS Negl Trop Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2022.02.019_b0090","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/cmi.2017.113","article-title":"Th1 cytokines, true functional signatures for protective immunity against TB?","volume":"15","author":"Zeng","year":"2018","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2022.02.019_b0095","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1080\/22221751.2021.1902245","article-title":"Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates","volume":"10","author":"He","year":"2021","journal-title":"Emerg Microbes Infect"},{"issue":"34","key":"10.1016\/j.vaccine.2022.02.019_b0100","doi-asserted-by":"crossref","first-page":"5666","DOI":"10.1016\/j.vaccine.2011.06.010","article-title":"Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone(R)) administered by intradermal and intramuscular route in healthy adults","volume":"29","author":"Frenck","year":"2011","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2022.02.019_b0170","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa2107456","article-title":"Safety, immunogenicity, and efficacy of the BNT162b2 COVID-19 vaccine in adolescents","volume":"385","author":"Frenck","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2022.02.019_b0105","doi-asserted-by":"crossref","unstructured":"Hofmann N, Grossegesse M, Neumann M, Schaade L, Nitsche A. Detection of neutralizing antibodies against SARS-CoV-2 by using a commercial surrogate virus neutralization ELISA: can it substitute the classical neutralization test? medRxiv. 2021:2021.10.12.21264881.","DOI":"10.1101\/2021.10.12.21264881"},{"issue":"12","key":"10.1016\/j.vaccine.2022.02.019_b0110","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1111\/trf.16714","article-title":"Surrogate test performance for SARS-CoV-2 neutralizing antibodies (nAbs) for convalescent plasma (CCP): how useful could they be?","volume":"61","author":"Wendel","year":"2021","journal-title":"Transfusion"},{"key":"10.1016\/j.vaccine.2022.02.019_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmpk.2021.100432","article-title":"Adenovirus vector-based vaccine for infectious diseases","volume":"42","author":"Sakurai","year":"2022","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1016\/j.vaccine.2022.02.019_b0120","doi-asserted-by":"crossref","unstructured":"Bricker TL, Darling TL, Hassan AO, et al. A single intranasal or intramuscular immunization with chimpanzee adenovirus-vectored SARS-CoV-2 vaccine protects against pneumonia in hamsters. Cell Rep 2021;36(3):109400.","DOI":"10.1016\/j.celrep.2021.109400"},{"issue":"4","key":"10.1016\/j.vaccine.2022.02.019_b0125","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.4049\/jimmunol.177.4.2208","article-title":"Intradermal delivery of adenoviral type-35 vectors leads to high efficiency transduction of mature, CD8+ T cell-stimulating skin-emigrated dendritic cells","volume":"177","author":"de Gruijl","year":"2006","journal-title":"J Immunol"},{"issue":"7","key":"10.1016\/j.vaccine.2022.02.019_b0130","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1093\/intimm\/dxz005","article-title":"Antigen presentation and adaptive immune responses in skin","volume":"31","author":"Honda","year":"2019","journal-title":"Int Immunol"},{"key":"10.1016\/j.vaccine.2022.02.019_b0135","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1146\/annurev-immunol-051116-052215","article-title":"Antigen-presenting cells in the skin","volume":"35","author":"Kashem","year":"2017","journal-title":"Annu Rev Immunol"},{"issue":"7","key":"10.1016\/j.vaccine.2022.02.019_b0140","doi-asserted-by":"crossref","first-page":"e40385","DOI":"10.1371\/journal.pone.0040385","article-title":"A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity","volume":"7","author":"Dicks","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2022.02.019_b0145","doi-asserted-by":"crossref","unstructured":"Dicks MD, Spencer AJ, Coughlan L, et al. Differential immunogenicity between HAdV-5 and chimpanzee adenovirus vector ChAdOx1 is independent of fiber and penton RGD loop sequences in mice. Sci Rep. Nov 18 2015;5:16756.","DOI":"10.1038\/srep16756"},{"issue":"19","key":"10.1016\/j.vaccine.2022.02.019_b0150","doi-asserted-by":"crossref","first-page":"12125","DOI":"10.1128\/JVI.79.19.12125-12131.2005","article-title":"Adenovirus receptors","volume":"79","author":"Zhang","year":"2005","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/j.vaccine.2022.02.019_b0155","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.virusres.2009.02.010","article-title":"Adenovirus receptors and their implications in gene delivery","volume":"143","author":"Sharma","year":"2009","journal-title":"Virus Res"},{"key":"10.1016\/j.vaccine.2022.02.019_b0160","doi-asserted-by":"crossref","unstructured":"Okayasu H, Sein C, Chang Blanc D, et al. Intradermal Administration of Fractional Doses of Inactivated Poliovirus Vaccine: A Dose-Sparing Option for Polio Immunization. J Infect Dis 2017;216(suppl_1):S161-S167.","DOI":"10.1093\/infdis\/jix038"},{"issue":"37","key":"10.1016\/j.vaccine.2022.02.019_b0165","doi-asserted-by":"crossref","first-page":"5500","DOI":"10.1016\/j.vaccine.2018.06.061","article-title":"Rabies vaccines: WHO position paper, April 2018 - Recommendations","volume":"36","author":"World Health Organization","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.02.019_b0175","doi-asserted-by":"crossref","unstructured":"Roozen GVT, Prins MLM, van Binnendijk R, den Hartog G, Kuiper VP, Prins C, et al. Tolerability, safety and immunogenicity of intradermal delivery of a fractional dose mRNA-1273 SARS-CoV-2 vaccine in healthy adults as a dose sparing strategy. medRxiv. 2021; 2021.07.27.21261116. doi: https:\/\/doi.org\/10.1101\/2021.07.27.21261116.","DOI":"10.2139\/ssrn.3892129"},{"issue":"9","key":"10.1016\/j.vaccine.2022.02.019_b0180","doi-asserted-by":"crossref","first-page":"990","DOI":"10.3390\/vaccines9090990","article-title":"Intradermal ChAdOx1 vaccine following two CoronaVac shots: a case report","volume":"9","author":"Singhatiraj","year":"2021","journal-title":"Vaccines (Basel)."},{"issue":"8","key":"10.1016\/j.vaccine.2022.02.019_b0185","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41577-021-00578-z","article-title":"Immunological mechanisms of vaccine-induced protection against COVID-19 in humans","volume":"21","author":"Sadarangani","year":"2021","journal-title":"Nat Rev Immunol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22001438?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22001438?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:10:54Z","timestamp":1759403454000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22001438"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":37,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S0264410X22001438"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.02.019","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity and safety of an intradermal fractional third dose of ChAdOx1 nCoV-19\/AZD1222 vaccine compared with those of a standard intramuscular third dose in volunteers who previously received two doses of CoronaVac: A randomized controlled trial","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.02.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}